Posts (26)

Thu, Mar 26 1:56pm · From Mayo Clinic patient to first regenerative sciences graduate

Chris Paradise

When Chris Paradise graduates from the Mayo
Clinic Graduate School of Biomedical Sciences
in May, it will be yet
another important milestone in his lifelong relationship with Mayo Clinic. The
one time Mayo patient and child of a Mayo Clinic nurse will be the first
student to graduate from the doctoral research training program known as the
Regenerative Sciences Training Program (RSTP). It will be a culmination of hard
work and dedication, backed by a positive attitude and team approach that is recognized
by his fellow students and colleagues.

“I was interested in science and fascinated by how
biological systems worked at a young age,” says Paradise. “I was the kid that
grew mold for the science fair project and stayed up late into the night
building a 3D model of the cell out of candy.”

This inherent interest and his involvement in sports at the
high school and college level fueled his fascination with musculoskeletal
biology and orthopedics. When Paradise was in high school he injured his
shoulder playing football — an injury that would have ended his athletic
career. He describes the care he received at Mayo as a turning point in his
life, which allowed him to play ball at a college level and sparked a further
interest in science and healing.

After receiving his bachelor’s degree from St. Olaf College
in Northfield, Minn., Paradise found himself intrigued by how science could be
applied to healing human health and disease. He wanted to continue his
education where he could make a difference in the lives of patients through
research.

In 2017, when Mayo Clinic announced
the RSTP
, one of the nation’s first doctoral research training programs in
regenerative sciences, Paradise knew he had found the perfect opportunity to
enhance his education and take advantage of all the resources the Center
for Regenerative Medicine
has to offer.

“The program was perfectly aligned with my desire to bring
knowledge from the lab to patients through regenerative science,” says
Paradise. “This was an opportunity to not only broaden my foundational
knowledge of stem cell and regenerative biology, but to connect with an
outstanding community of students, scientists and physicians leading the way in
the field of regenerative medicine.”

Paradise has had a productive start to his research career
during his time in graduate school. He credits his laboratory mentors and the
collaborative environment of Mayo Clinic for the opportunity to contribute to a
wide array of exciting research papers. Chris has contributed to over 20
research articles published in journals such as Nature Biomedical Engineering, Stem
Cells and Development
, and the Journal
of Biological Chemistry
, in addition to publishing two first-author papers
of his own.

He says the comprehensive approach of Mayo Clinic — being
able to take an idea or problem to a research lab and subsequently translating
a solution into patient care — is the reason he chose to study at Mayo. He
landed in the lab of Andre
van Wijnen, Ph.D.
, now his research mentor, where he began as a research
trainee. After this full-time experience in a biomedical laboratory, Paradise
applied for the Ph.D. Program in
biomedical science at Mayo
Clinic Graduate School of Biomedical Sciences to continue his education.
Two years after starting in Dr. van Wijnen’s lab, he joined the group as a
full-time graduate student to investigate new strategies for bone and cartilage
repair. Shortly after, he was accepted into the RSTP.

“Chris has set the bar high for future students,” says Dr.
van Wijnen. “Beyond his incredible research achievements that are truly off the
charts, he is has been a model citizen of the Mayo Clinic academic community.
He was active in further development of coursework as part of the graduate
school’s regenerative medicine curriculum, participated in journal clubs, and
served as a teaching assistant for several courses on campus.”

Paradise and the team in Dr. van Wijnen’s lab are actively
investigating new approaches for musculoskeletal regeneration using adult stem
cells and new drugs that may lead to a better understanding of bone
regeneration. They’re working to improve the current standard of care in
orthopedic repair and restoration of the human joint — bone, cartilage,
ligament and tendon.

“Chris’ attitude and work ethic embodies the core values of
Mayo Clinic,” says Dr. van Wijnen. “He is always willing to help and is the
first to volunteer even if it is outside of his responsibilities — even helping
to teach and mentor others in the lab.”

Outside of the lab, Paradise brings another value to his
fellow students and colleagues at Mayo Clinic — he grew up just down the road from
Rochester in Mantorville, Minn. His mother has been a nurse at Mayo for over 30
years, and he has been a regular patient at Mayo throughout his life. 

“Beyond science, Chris has been the source of local
information to those who are new to the community,” says Amel Dudakovic, Ph.D.,
a senior research associate who has also served as a mentor to Chris during his
time in the lab. “On numerous occasions, he has spent his personal time helping
others navigate local events and culture.”

Additionally, Paradise gives back to the community through
student-led community outreach organizations such as Brainwaves, a group
dedicated to teaching local middle and high school students about the brain.

He successfully defended his thesis March 4 in front of a
large audience of friends, family, and Mayo Clinic faculty. He will graduate
from the Mayo Clinic Graduate School of Biomedical Sciences on May 17.

The RSTP continues to be a priority for the Center for Regenerative Medicine and the graduate school, as a way to prepare the next generation of scientists to accelerate the discovery, translation and application of cutting-edge regenerative diagnostics and therapeutics.

Mayo Clinic Center for Regenerative Medicine supports over
20 students in the RSTP, which accepts 3-4 students per year and has students
on all three Mayo graduate school campuses in Arizona, Florida and Rochester.
Students in the program graduate with a doctorate in biomedical sciences with
an emphasis in regenerative sciences and their track of choice.

“The sky is the limit at a place like Mayo with the
resources we have here as students,” says Paradise. “I have been fortunate to
collaborate with leaders in the regenerative medicine field and the orthopedics
department on many projects.” He adds that the last six years have been
incredibly enjoyable thanks to his friends and colleagues at Mayo Clinic.

Fri, Mar 6 9:30am · Improving remyelination for spinal cord injury: Arthur Warrington, Ph.D.

Mayo Clinic researchers are probing potential ways to unleash the
human body’s ability to heal neurological disorders like spinal cord injuries
or multiple sclerosis. Myelin is the protective covering that surrounds
nerve fibers in the brain, optic nerves and spinal cord. Demyelination, or injury to the myelin, slows electrical signals between
brain cells, resulting in loss of sensory and motor function. Through
funding from Regenerative Medicine Minnesota,
Mayo Clinic researcher Arthur
Warrington, Ph.D.
, is investigating the ability of a human antibody to
encourage the nervous system to regenerate its own myelin.

“As we age the myelin healing process takes longer, partly
due to the aging immune system,” says Dr. Warrington. “We’re taking the concept
of regenerative and therapeutic antibodies for multiple sclerosis (MS) and
looking at whether that can be translated to rescue spinal cord injuries.”

A unique human antibody, discovered at Mayo Clinic, completed early stage clinical trial in patients with MS without any side effects. Because it was found to be safe in humans, researchers can now design studies for patients across the spectrum of neurological disease where remyelination would be of benefit, such as spinal cord injury, traumatic brain injury and stroke.

Fri, Feb 28 1:57pm · Student-led interest group helps to build the future regenerative medicine workforce

Medical students, Jake Besch-Stokes, Christian Rosenow, Steven Herber and Tyler Jarvis

Educating the next-generation of regenerative
physician-scientists is a strategic priority of the Mayo
Clinic Center for Regenerative Medicine
. And, as the field advances beyond
traditional management of symptoms to addressing the underlying cause of
disease through curative solutions, medical education must evolve to capitalize
on this ongoing evolution. At Mayo Clinic, an interest group formed by medical
students is sharing new knowledge in regenerative medicine beyond the
classroom.

At the recent World Stem
Cell Summit
, four medical students from the Mayo Clinic Alix School of
Medicine in Arizona showcased their research. The students presented five Mayo
Clinic Center for Regenerative Medicine posters to an international audience
that included more than 2,000 physicians, scientists and bio-industry
professionals. 

“This educational approach highlights the importance of learner-initiated,
patient-focused education, especially in a constantly evolving field like
regenerative medicine,” says Saranya Wyles, M.D., Ph.D., assistant professor at
Mayo Clinic and a course director for the Regenerative Medicine and Surgery curriculum.
“This interest group is inspiring other students to get increasingly involved in
regenerative sciences equipped with peer-developed education tools to engage
the next generation.”

Mayo Clinic offers curricula in regenerative sciences
across all five of its schools within the educational shield and is pioneering
a patient-centered medical school selective in regenerative medicine and
surgeries. The medical students who presented at the World Stem Cell Summit emerged
from that selective so inspired that
they have formed a regenerative medicine interest group to educate their
peers on topics in regenerative medicine. The medical students, Steven Herber and
Tyler Jarvis, started the group; later recruiting Jake Besch-Stokes, Christian
Rosenow and Josh Spegman to serve on the leadership team. Collectively,
they are increasing awareness and interest in regenerative medicine and surgery
topics.  

Steven Herber at the World Stem Cell Summit

“A group of us attended the Regenerative
Medicine and Surgery Selective
together in 2019,” says Steven Herber,
a medical student at Mayo Clinic Alix School of Medicine. “It was an experience
that left us wanting to bring others together who were interested in regenerative
medicine in order to increase exposure of regenerative sciences topics to
students and connect students to researchers.”

While the idea of student-led interest groups is not new to the medical
school, the group wanted to go beyond the tradition of hosting speakers and
organizing educational events. In its first year, the group spearheaded
innovative research centered on regenerative medicine education, including the
formation of the medical student interest group, early exposure to regenerative
science in elementary schools, and the availability of regenerative medicine
curricula in medical schools across the United States. They have also built a
repository of research mentors in regenerative medicine and made the list
available to all students in the school, allowing students easy access to
regenerative medicine experts.

Tyler Jarvis at the World Stem Cell Summit

This up and coming group of medical students is also looking to
teach the next-generation of young learners. The group recently met with elementary
school children in grades 3-6, gauging their ability to understand current
fundamental concepts of regeneration and the body’s building blocks that allow
wound healing and repair after injury.

“We found that the elementary aged students are excited about and able
to engage in lessons on stem cell biology and regenerative medicine,” says
Jarvis. “Next, we will work with regenerative medicine experts at Mayo Clinic
to further develop age-appropriate curricula in an effort to inspire future
scientists and physicians at a young age.”

“We’re committed to training the emerging workforce in regenerative science and technology,” says Richard Hayden, M.D., Center for Regenerative Medicine director of education. “These students are researching the best training and educational tools for regenerative medicine in order to enable future physicians and scientists to better understand and care for patients.”

Fri, Feb 14 12:35pm · Evolution of cardiac regeneration

February
is American Heart Month, a time to acknowledge advancements in a new generation
of care. This year focus is placed on repairing damaged heart tissue and
restoring heart function after a heart attack. The Mayo Clinic Center for
Regenerative Medicine is leading research into cardiac regeneration.

Accounting
for nearly 20 million of all deaths, heart
disease
is the leading cause of death worldwide. Currently,
there is no way to replace muscle that has died after a heart attack as damage
is often irreversible. Mayo Clinic researchers and clinicians are seeking to create
innovative and more affordable and accessible cardiac regenerative therapies to
restore heart muscle.  

Atta Behfar, M.D., Ph.D.

“Cell
therapy has pioneered our ability to drive regenerative medicine forward,” says
Atta
Behfar, M.D., Ph.D.
, director, Mayo
Clinic Van Cleve Cardiac Regenerative Medicine Program

in the Center
for Regenerative Medicine
. “In order to be impactful in the next
decade, cardiac regeneration efforts need to overcome current hurdles through
innovation and development of new technologies that are both fiscally and
logistically realistic.”

With
the clinical experience accumulated in cardiovascular regeneration both at Mayo
Clinic and globally, we now know that a tailored approach will likely provide
the best outcomes. For a heart attack and stroke, which require urgent care, off-the-shelf
cell-independent technologies that can be stored right at the bedside may be most
effective. In contrast, for more chronic conditions like heart failure where a
sustained regenerative impulse is required, cellular or gene-based therapies
may provide a more robust end result. As the regenerative toolkit continues to
grow, with new modalities to deliver restoring cues to the heart, so will our
aptitude in offering new solutions to patients in need.

Michael Sabbah, M.D.

“Cell-based
technologies have historically been poorly compatible with acute syndromes due
to the emergent need for care,” says Michael Sabbah, M.D, Mayo Clinic
cardiologist and researcher in the Mayo Clinic Van Cleve Cardiac Regenerative
Medicine Program. Establishment of a room temperature-stable product that can
be left on the shelf in a surgical or procedure room would allow the use of regenerative
therapies at the point of care following stent implantation.”

A
case in point, established in the Center for Regenerative Medicine, is the use of
regenerative vesicles, termed exosomes which are the active ingredient of
regeneration. Exosomes are packages of signaling molecules that act as
communication links between cells in the regenerative healing process. They are
like an envelope with instructions for healing that one cell mails to another. They
can modify the immune response and facilitate blood vessel growth. This
technological platform is now under active investigation at Mayo Clinic to
evaluate its ability to protect the heart against injury in heart attack.

“In
the laboratory, employment of exosomes has been successful,” says Dr. Sabbah. “Our
goal is to leverage what we have learned to establish new tools to treat
patients with acute cardiovascular syndromes, who currently suffer from
devastating and long-lasting deficits. By utilizing a cell-independent
platform, our ultimate goals is to develop regenerative technologies that may
be employed by providers in a broad array of clinical areas, unencumbered by
logistical hurdles that are sometimes seen with other regenerative approaches.”

Although
the study and use of exosomes has progressed in the lab, researchers acknowledge
that this is simply one example of the type of technological advance poised to broaden
the scope of cardiac regeneration. Through the optimization of biologics-based
science, researchers in the Mayo Clinic Van Cleve Cardiac Regenerative Medicine
Program are expected to start clinical testing later this year.

“Cardiac
regeneration has historically paved the way forward in establishing novel
biologics-based platforms. Our hope is that as new approaches to restore heart
function are implemented, they will inspire use of similar principles across medical
and surgical specialties,” says Dr. Behfar. “In order to ensure that all
patients receive the highest standard of care, we must utilize the discovery
process not just as a paradigm to achieve translational successes, but even
more importantly as a modality to break socioeconomic divides and improve
access to care.”

###

Thu, Jan 30 1:01pm · Bacteria for regenerating lung homeostasis to treat COPD: Veena Taneja, Ph.D.

Mayo Clinic is researching a cause and regenerative approach to treatment for one of the most common and deadly forms of lung disease. Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that makes it difficult to breath. It is also known as emphysema and chronic bronchitis. According to the Minnesota Department of Health, COPD is the fifth leading cause of death in Minnesota, and 50% of Minnesotans with COPD are undiagnosed. Through a grant from Regenerative Medicine Minnesota, Mayo Clinic immunologist Veena Taneja, Ph.D., is researching regenerative methods to treat COPD.

The research, currently being
done in mice, is looking at the role of smoking as a cause of COPD. Dr. Taneja’s
team has developed an expedited model of cigarette smoke-induced COPD in mice
that express human immune genes and mimic human immune response.  

“Although initially
thought sterile, healthy lungs have diverse bacteria, and individuals who have
a history of smoking and have been diagnosed with COPD are missing a bacterium
that is typically present in healthy individuals,” says Dr. Taneja. “We’ve been
able to isolate and reintroduce the missing human oral bacterium in to the lungs
of mice to correct
the microbial imbalance in our laboratory.”  

If successful this research could
lead to a better understanding of how the human body uses endogenous bacteria that
naturally present in the body to heal from within. The treatment could ease
symptoms, improve lung function, and stabilize the immune system to decrease
inflammation.

“Since we plan to create a
balance with the bacteria already residing inside every human, it is
anticipated that treatment should not result in major side effects,” adds Dr.
Taneja.

Learn more about Dr. Taneja’s
research in the video below:

Sun, Jan 5 10:18pm · Stem cells in space: A new frontier in regenerative medicine training

Rawan Al-Kharboosh

A Mayo Clinic graduate student is looking to the stars as a new way to advance regenerative therapies for cancer. Rawan Al-Kharboosh, a Ph.D. candidate at Mayo Clinic’s Florida campus, is investigating how stromal vascular fraction stem (SVF) cells react in microgravity and if that may be applied to fight the most deadly type of brain cancer — glioblastoma. SVF cells are a type of cells with the potential to regenerate tissue.

Treatment of the glioblastoma has seen little improvement in
outcome in the past decades, with a dismal prognosis and a devastating median
survival of 14.6 months. Despite vigorous treatment combinations of surgery,
chemotherapy and radiation, there is nearly a 100% recurrence rate. The
microscopic cells left behind after surgery – the ones that are not seen on an
MRI – are responsible for its resistance and ultimate relapse.

Al-Kharboosh is enrolled in the neuroscience track of Mayo’s Ph.D. program and is a scholar in the Regenerative Sciences Training Program (RSTP), supported by the Mayo Clinic Center for Regenerative Medicine. The program, led by Jennifer Westendorf, Ph.D., and administered through the Mayo Clinic Graduate School of Biomedical Sciences, is designed to prepare the next generation of researchers and advance regenerative sciences into clinical practice. 

In January, Al-Kharboosh’s research cells are scheduled to
rocket on a suborbital flight, in which it reaches the point of weightlessness
but remains below the altitude where it can orbit Earth. She will examine how microgravity affects SVF cells derived from
human fat (adipose tissue), and if stem cells can be engineered in a way to
allow for same-day engineering. The results of her experiment may shed light on
whether SVF can be engineered in microgravity and if these cells could be reintroduced
to the brain during cancer surgery to promote healing.

“We isolate stromal vascular fraction derived from human fat
(adipose) tissue directly from patients in the operating room,” says
Al-Kharboosh. “We are exploring the possibility of engineering these cells with
nanoparticles to target and combat brain cancer by releasing a therapeutic
cargo.”

When returned to the patient, engineered adipose-derived
cells act as vehicles to target and combat the cancer cells. Right now, this is
done in a laboratory setting with the cells adhering to and growing on a
plastic plate. It takes a few hours for the cells to adhere to the plastic and
even longer for their growth. Al-Kharboosh was curious to find ways in which
the modified cells could be engineered in suspension rather than on a plate.

Engineering cells in suspension avoids laboratory
processing, is less expensive, more accessible and explores a platform where
“same-day” engineering is possible and could be done by a physician in the
operating room while patient is at the bedside.  

Al Rawan Al-Kharboosh and her mentor, Alfredo Quinones-Hinojosa, M.D., the William J. and Charles H. Mayo Professor

“Rawan’s work is extraordinary. In some ways revolutionary,” says Al-Kharboosh’s mentor, Alfredo Quinones-Hinojosa, M.D., a neurosurgeon on Mayo Clinic’s Florida campus. “She is helping to find potential therapies — and maybe one day cures — for patients with cancer and other neurological diseases. It is highly risky, but it also could be highly rewarding.”

Rawan says the students in the Regenerative Sciences
Training Program meet during class seminars and journal clubs to discuss their
research. They provide input on each other’s work and discuss ways to navigate
the discovery, translation and application of regenerative research and
therapeutics, and the more difficult topics of regulatory, political and
ethical considerations of regenerative medicine and stem cells.

Mayo Clinic Center for Regenerative Medicine supports 17 students
in the RSTP program, including Al-Kharboosh. The center selects student who
will go on to careers that advance the regenerative sciences field and bring
new regenerative therapies to patients. Al-Kharboosh says her dream is to be
the CEO of a large biotech company that discovers and develops regenerative
products for patients.

Read more about Rawan Al-Kharboosh and her research in Discovery’s
Edge
.

Dec 19, 2019 · Off the Shelf Vessels: A Regenerative Approach for Coronary Artery Bypass

Growing blood vessels in a lab for human use may sound like a futuristic dream. However, Mayo Clinic researchers are seeking to do just that to advance a regenerative approach to coronary bypass graft surgery. Through a Regenerative Medicine Minnesota grant, a Mayo research team is developing tissue that could grow into a blood vessel to be used in place of a patient’s own blood vessels to complete the heart bypass.

Coronary artery disease, also known as ischemic heart disease or coronary heart disease, is caused by narrowing or blocking of the coronary arteries that supply blood to the heart muscle. Standard of care surgery relies on harvesting a vessel from the patient to create a bridge around the obstructed coronary vessel and restore normal blood flow. This approach, however, increases a patient’s surgical time and can result in increased pain and potential complications.

“Ischemic heart disease affects over 130,000 Minnesotans,” says Leigh Griffiths, Ph.D., MRCVS. “Through our research, we are developing and exploring a safe and effective vessel replacement for use in coronary artery bypass graft procedures to overcome limitations associated with current approaches.”

Using a tissue engineered vessel grown in a lab eliminates
the need to take a vessel from the patient’s own leg, arm or chest — that’s one,
instead of two surgeries, for the patient.

“Our previous research has developed animal-derived biomaterials
that are manipulated to allow patients bodies to accept them as their own.” says
Dr. Griffiths. “Importantly, such biomaterials are highly regenerative as they
contain coding information that helps body heal. These coding signals guide
pro-regenerative responses, which ultimately result in the biomaterial being
replaced by the patient’s own tissue.”

As principal investigator of the Cardiovascular Engineering Research Laboratory at Mayo Clinic, Dr. Griffiths leads a team dedicated to improving treatment of cardiovascular disease through discoveries in transplant immunology, regenerative medicine and tissue engineering. Their ongoing research may have diagnostic and therapeutic implications for patients with congenital cardiovascular defects, heart valve disease, aortic aneurysm, aortic dissection, heart transplant, peripheral artery disease and coronary artery disease.

More information:

Lab Website: Vascular Tissue Engineering Research Laboratory

Dec 12, 2019 · Regenerative Product Could Provide New Option for Women with Mesh Exposure Following Pelvic Reconstructive Surgery

Cassandra Kisby, M.D., and John Occhino, M.D.

Research is advancing a regenerative solution for a quality of life-limiting complication of mesh-based surgical repairs for stress urinary incontinence and pelvic organ prolapse in women. While mesh-based surgical treatments are durable and provide symptom relief for a great number of patients, there is a risk of mesh complications following surgery, such as mesh exposure. In this situation, many patients require an additional surgery to revise their implant. Mayo Clinic research, supported by the Center for Regenerative Medicine, is testing a regenerative approach to restoring form and function without additional corrective surgery in the setting of vaginal mesh exposure.

Vaginal prolapse is a medical term for a condition that
leads to bulging of the pelvic organs, such as the bladder, uterus or rectum.
It happens when ligaments and muscles on the pelvic floor stretch and weaken,
no longer providing adequate support. Those internal organs slip down, bulging
through the vagina wall, causing prolapse. Alternatively, women can also
experience accidental leakage of urine with activity or cough, laugh and
sneeze. This is termed stress urinary incontinence. Often linked to child
birth, obesity or aging, incontinence and prolapse affect many women.  

Women with vaginal prolapse or urinary incontinence may
choose to undergo placement of mesh if they have failed conservative therapies.
Mesh is used in gynecology surgery to lift and support the pelvic organs,
typically the bladder or uterus, relieving the pressure that caused the pelvic
floor defect. However, like all surgery, there are potential risks. The mesh
sometimes wears through the vaginal walls, causing vaginal discharge and
possibly discomfort for women and their partners. Therein lies the dilemma: should
there be another surgery to remove the mesh or would the patient prefer to live
with the symptoms?

Mayo Clinic researchers are studying a new regenerative
option, called purified exosome product (PEP) to treat a complication of the
use of mesh in gynecologic surgery. Research, currently in animal models, is looking
at whether PEP could promote regeneration of tissue that would grow over the
mesh and restore the vaginal wall.

“While gynecological mesh is a viable option for many women, we wanted to create a non-surgical reparative option for our patients,” says John Occhino, M.D., clinician-scientist in gynecologic surgery with specialty training in urogynecology and pelvic reconstructive surgery. “We are studying the use of PEP to correct one of the most common side effects of mesh placement, the exposure of mesh through the vaginal wall after surgery.”

Exosomes are small membrane-bound vesicles secreted into the
body’s cellular environment. Imagine bubbles carrying a signal that tell the
body to regenerate and renew. For example, when the skin is scratched, exosomes
are sent to repair the skin. By delivering a high dose of purified exomes, researchers
can recruit numerous cells and pathways to help heal the tissue back to its original
state.

“Our research injects an exosome gel into the vaginal
tissues of a preclinical model of mesh exposure,” says Cassandra Kisby, M.D., female
pelvic medicine and reconstructive surgery fellow. “Four weeks after treatment we saw the vaginal
tissues had repaired and covered the prior mesh exposure.”

The regenerated tissues were physiologic, adds Dr. Kisby, meaning
there were new blood vessels, the tissues had normal amounts of collagen, and
there was minimal scaring.

Microscopic immunohistochemistry images showing areas of implanted mesh. The first image, treated with purified exosome product (PEP), has robust tissue regrowth (green) over the mesh and growth of the epithelium (red). The second did not receive PEP and has thin, broken tissue with little growth.

While this research is currently only being done in animal
models, Drs. Occhino, Kisby and team are working to develop a phase 1 clinical
trial to test the safety of PEP in humans within the next year.

“This technology opens the door for numerous applications in gynecology, including birth injury and repair, urinary incontinence, and fistulas.” says Dr. Kisby. “Our goal is to create a women’s health regenerative medicine program to help expedite the research and translation of this technology into clinical  practice.”

###
The Center for Regenerative Medicine recognizes Michael S. and Mary Sue Shannon for their generosity and support in advancing regenerative women’s health research.

Contact Us · Privacy Policy